For Medical Professionals

Lean mass loss is not a side effect.
It is a predictable consequence.

GLP-1 and dual GIP/GLP-1 agonists are a transformative advance in obesity medicine. But the evidence is unambiguous: substantial lean body mass loss accompanies the weight reduction these medications produce — and it frequently exceeds expected physiologic benchmarks. Just Right GLP-1™ extends your care — providing the personalized protein, supplement, and resistance-training support the guidelines call for, with a depth of follow-up that's hard to fit into a busy practice.

Physician Statement
"Resistance training, adequate protein, and vitamin D supplementation are not extras. They are the standard of care for safe, sustainable weight loss on these medications."
— Dr. Jeremy Burnham, MD
Built on the guidelines
ADA Standards of CareEndocrine Society CPGACLM · ASN · OMA · TOS Joint Advisory

The weight comes off.
So does the muscle.

A 2026 systematic review in Annals of Internal Medicine of 36 RCTs found the median share of weight loss attributable to muscle-based indices was 34.9%, with 68% of incretin interventions exceeding the ~25% lean-loss benchmark expected during weight reduction.1

Across the major trials, a striking share of what patients shed is lean tissue — including the skeletal muscle that underpins strength, metabolic rate, balance, and long-term independence. In the landmark STEP 1 trial of semaglutide, more than a third of the average weight reduction was lean body mass rather than fat.1 In SURMOUNT-1, tirzepatide reduced total lean mass by roughly eight and a half percentage points.2

And the pattern carries an uncomfortable irony: the agents that produce the most weight loss tend to be the least protective of muscle. The more effective the medication, the more deliberately lean mass has to be defended — yet that protection is almost never built into the prescription itself.3

Patients who regain weight after discontinuing a GLP-1 receptor agonist regain mostly fat, not muscle — potentially compounding the risk of sarcopenic obesity, the phenotype tied to the worst cardiometabolic outcomes.
A predictable, and preventable, trajectory18

This is not a cosmetic concern.

Low muscle mass is an independent predictor of hard clinical outcomes — across community-dwelling adults, outpatients, inpatients, and nursing home residents.17

2.0×
all-cause mortality with low muscle mass
HR 2.00 · Ref 4
3.6×
mortality in sarcopenia by EWGSOP criteria
OR 3.60 · Ref 5
3.0×
functional decline, with higher falls & hospitalization
OR 3.03 · Ref 5
↑ CVD
accelerated cardiovascular disease, falls & fractures
Ref 6
Prescribing a GLP-1 receptor agonist without addressing muscle preservation is, on the current evidence, an incomplete treatment plan. The question is no longer whether structured support is needed — it is how to deliver it at scale.

Medication alone
is not enough.

Every FDA-approved anti-obesity medication is approved as adjunctive therapy to a reduced-calorie diet and increased physical activity. This is not optional language — it is the labeled indication.1920

GLP-1s should be prescribed together with a structured exercise program, aiming for regular strength training at least 3× weekly plus at least 150 min of moderate-intensity aerobic exercise weekly to preserve muscle and bone mass.
2025 Joint Advisory — ACLM · ASN · OMA · The Obesity Society7

The same advisory is explicit that increased protein intake alone is likely inadequate to preserve muscle mass in the absence of structured resistance training.7 The recommendation is echoed across the field — adjunctive lifestyle intervention is not a footnote, it is the consensus.21

ADA Standards of Care 20268Endocrine Society CPG10JAMA 2026 — Lifestyle & Incretins9JAMA Internal Medicine 202511

What prescribers know
vs. what they can deliver.

The evidence is clear. The guidelines are explicit. But four realities of practice stand between the recommendation and the patient.

01 · Time

The visit can't hold it

The average primary-care encounter does not allow for individualized protein calculations, resistance-training programming, supplement counseling, and ongoing body-composition monitoring.

02 · Scope

The expertise sits elsewhere

Most prescribers are not exercise physiologists, dietitians, or sports nutritionists — and referral pathways to those specialists are often fragmented or unavailable.

03 · Adherence

Patients are left to navigate alone

Without a structured, accessible program, patients improvise protein targets, supplement choices, and exercise routines — often from conflicting, unvetted sources.

04 · Real Life

The plan has to fit a real day

Even the right plan only helps if the patient can actually live it — getting the right supplements, fitting training into a real schedule, and keeping it going for months. Everyday friction at any step quietly stalls progress between visits.

The evidence is clear. The guidelines are explicit. The gap is delivery.

The evidence behind
each pillar.

Pillar 1 · Protein

For patients on GLP-1s, achieving adequate protein is particularly challenging due to reduced appetite and taste aversions. Protein-rich foods should be consumed first in meals, and supplementation with high-protein shakes, bars, or fortified products may be necessary.7

Pillar 2 · Resistance Training
Reduces lean body mass loss by 50–95% during caloric restriction — and preserves bone density.1112

In a randomized trial, one year of combined GLP-1 therapy with exercise training preserved bone mineral density, while GLP-1 therapy alone decreased it. The combination also produced larger reductions in abdominal fat and systemic inflammation.22

Pillar 3 · Creatine + HMB
Creatine

A meta-analysis confirmed creatine supplementation increases fat-free mass (WMD 0.82 kg; 95% CI 0.57–1.06) while reducing body-fat percentage, with effects most robust when combined with resistance training. Critically, under catabolic (energy-deficit) conditions, creatine inhibits the ubiquitin-proteasome pathway responsible for muscle protein breakdown and protects mitochondrial function.13

HMB (β-Hydroxy-β-Methylbutyrate)

The ISSN position stand confirms HMB acts through a dual mechanism: enhancing muscle protein synthesis via mTORC1 activation and suppressing breakdown via the ubiquitin-proteasome pathway. An umbrella review of meta-analyses found HMB significantly increased fat-free mass and muscle-strength indices; in models of sustained energy deficit, it attenuated muscle loss and maintained grip strength.1415

Pillar 4 · Vitamin D
L-shaped association with sarcopenia risk — highest below 20 ng/mL, leveling off above it.1623

Vitamin D plays a direct role in muscle protein synthesis, muscle-cell proliferation and differentiation, and mitochondrial function. Deficiency is highly prevalent among patients with obesity and those undergoing rapid weight loss, and is associated with impaired muscle function and increased fall risk.

Because the degree of deficiency varies widely among individuals, personalized dosing — rather than a one-size-fits-all approach — is essential. Just Right D™ uses evidence-based personalization to determine individual doses from 1,000 to 4,000 IU/day based on multiple patient-specific factors.

What Just Right GLP-1™
provides for your patients.

Personalized protein assessment — individualized daily targets from body composition, current intake, and GLP-1 status.

Daily HMB + creatine — evidence-based doses in a convenient daily format.

Personalized vitamin D (Just Right D™) — individualized 1,000–4,000 IU/day dosing with a six-month supply and reassessment.

Smartphone-delivered resistance training — short, practical, at-home exercises designed for adherence. No gym required.

Physician-created education — why muscle matters, how the program works, and when to consult their prescriber.

Six-month reassessment — because needs change as patients progress through weight loss.

Why refer
your patients.

1

It aligns with the standard of care.

Every major guideline — ADA, the Endocrine Society, the Joint Advisory — recommends structured lifestyle intervention alongside anti-obesity pharmacotherapy. Just Right GLP-1™ operationalizes these recommendations.78910

2

It addresses a gap that's hard to fill in practice.

Individualized protein planning, supplement dosing, resistance training programming, and ongoing reassessment require time and expertise that are hard to deliver in many practices at the frequency the evidence demands.

3

It complements — never replaces — your care.

The program is designed to work alongside the prescriber's treatment plan. Patients are encouraged to share their program recommendations with their physician. No medications are prescribed. No medical advice is given that supersedes the prescriber's judgment.

4

It is evidence-based.

Every component — protein, creatine, HMB, vitamin D, and resistance training — is grounded in peer-reviewed research and endorsed by major medical societies as part of comprehensive obesity care.711131416

5

It prioritizes adherence.

The most effective program is the one patients actually follow. Supplements are delivered to the door. Exercises are delivered to the smartphone. Protein sources are chosen by the patient based on personal preference. The program is designed for real life.

The literature is clear. The question isn't whether — it's how to deliver it.

Two simple ways to begin. Request a referral kit for your practice, or book a short call to see how Just Right GLP-1™ fits the patients you're already treating.

Prefer email? Reach us directly at [contact email].

Selected References

  1. Batsis JA, et al. Effect of incretin-based and nonpharmacologic weight loss on body composition: a systematic review. Ann Intern Med. 2026. PubMed
  2. Look M, et al. Body composition changes during weight reduction with tirzepatide in SURMOUNT-1. Diabetes Obes Metab. 2025;27(5):2720-2729. Link
  3. Karakasis P, et al. Effect of GLP-1 RAs and co-agonists on body composition: systematic review and network meta-analysis. Metabolism. 2025;164:156113. PubMed
  4. Xu J, et al. Sarcopenia is associated with mortality in adults: a systematic review and meta-analysis. Gerontology. 2022;68(4):361-376. PubMed
  5. Beaudart C, et al. Health outcomes of sarcopenia: a systematic review and meta-analysis. PLoS One. 2017;12(1):e0169548. PubMed
  6. Damluji AA, et al. Sarcopenia and cardiovascular diseases. Circulation. 2023;147(20):1534-1553. PubMed
  7. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory (ACLM, ASN, OMA, TOS). Am J Clin Nutr. 2025;122(1):344-367. Link
  8. American Diabetes Association. Obesity and weight management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S166-S182. Link
  9. Kushner RF, Chao AM, Wadden TA. Lifestyle modification and incretin-based therapy for obesity. JAMA. 2026. Link
  10. Apovian CM, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362. Link
  11. Mehrtash F, Dushay J, Manson JE. Integrating diet and physical activity when prescribing GLP-1s. JAMA Intern Med. 2025;185(9):1151-1152. Link
  12. Jensen SBK, et al. Bone health after exercise alone, GLP-1 RA, or combination treatment. JAMA Netw Open. 2024;7(6):e2416775.
  13. Forbes SC, et al. Creatine ingestion strategies on lean tissue mass and strength in older adults: a meta-analysis. Nutrients. 2021;13(6):1912.
  14. Rathmacher JA, et al. ISSN position stand: β-hydroxy-β-methylbutyrate (HMB). J Int Soc Sports Nutr. 2025;22(1):2434734. PubMed
  15. Bideshki MV, et al. Ergogenic benefits of HMB on body composition and strength: an umbrella review. J Cachexia Sarcopenia Muscle. 2025;16(1):e13671.
  16. Sha T, et al. Genetic variants, serum 25(OH)D, and sarcopenia: a Mendelian randomization analysis. JAMA Netw Open. 2023;6(8):e2331558.
  17. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393(10191):2636-2646. PubMed
  18. Chavez AM, Carrasco Barria R, León-Sanz M. Nutrition support whilst on glucagon-like peptide-1 based therapy. Is it necessary? Curr Opin Clin Nutr Metab Care. 2025;28(4):351-357. PubMed
  19. Gudzune KA, Kushner RF. Medications for obesity: a review. JAMA. 2024;332(7):571-584. Link
  20. U.S. Food & Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Link
  21. Lieberman DE, Aslan DH, Heymsfield SB. The conundrum of exercise for weight management in the GLP-1 receptor agonist era. JAMA. 2026. Link
  22. Lundgren JR, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384(18):1719-1730.
  23. Prokopidis K, et al. Effect of vitamin D monotherapy on indices of sarcopenia in community-dwelling older adults: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2022;13(3):1642-1652.